Search
Omega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationaltriglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA Label][A176687]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower
Mixtures: Mi-Omega NFProducts: OMACOR 1000 mg Weichkapseln, Zodin 1000 mg - WeichkapselnModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesProducts: MODIODAL 100 MG TABLET, 30 ADET, CRALİUM 100 MG TABLET, 30 ADETMivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnIt binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Products: MIVACRON INJECTION 10 mg/5 ml, MİVACRON 10 MG/5 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADETRabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalRabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...
Mixtures: RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞE, RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersParoxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSynonyms: (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidineFosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 SubstratesProducts: FOSAPRANT 150 MG İ.V. İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, FOSEMRED 150 MG/VIALBotulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.
Products: BOTOX 100 U. ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ, 1 ADET, NEURONOX® 100 UIAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalBy replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).
Products: STRENSİQ 40 MG/1.0 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 80 MG/0.8 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETPramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalRLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876]. … In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].
Products: MIPEXOBEX TM 1.0 MG, PACTO 0,5 MG TABLET, 100 ADETBetahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is thought to reduce symptoms through its actions on histamine receptors.
Products: BETARIS 8 MG/ML ORAL DAMLA, 100 ML, BETARİS 24 MG TABLET, 100 ADET